Series D financing
Odyssey Therapeutics Secures $213M Series D to Accelerate Autoimmune Clinical Portfolio
Odyssey Therapeutics; Series D financing; $213 million; autoimmune diseases; clinical pipeline; preclinical programs; precision immunomodulation; RIPK2 inhibitor; PROTAC technology; investors
Fierce Biotech Fundraising Tracker ’25: Grin Raises $140M Series D and Strikes Major Angelini Deal; Syndeio Secures $90M
Grin Therapeutics; Series D financing; radiprodil; Angelini Pharma; Blackstone Life Sciences; Syndeio; biotech fundraising; neurodevelopmental disorders; pharma partnerships
Neptune Medical Secures $97M in Funding, Launches Jupiter Endovascular Subsidiary
Neptune Medical, Jupiter Endovascular, GI robotics, endovascular technology, Series D financing, medical device innovation, healthcare technology